Compound Contains Two Or More C(=o)o Groups Indirectly Bonded Together By Only Conalent Bonds Patents (Class 514/533)
  • Patent number: 11224560
    Abstract: The present invention relates to a composition, preferably a cosmetic composition for a keratin substance, preferably skin, comprising: (a) at least one associative thickener; (b) at least one specific alkyleneoxide derivative; (c) at least one nonionic surfactant, other than (b), with an HLB value of 13.0 or less; and (d) water. The composition according to the present invention can prevent soaping and can provide excellent texture, when used, while providing sufficient thickening or gelling effects.
    Type: Grant
    Filed: July 26, 2016
    Date of Patent: January 18, 2022
    Assignee: L'OREAL
    Inventors: Shinobu Mitsuda, Makoto Saito
  • Patent number: 11166932
    Abstract: The present invention relates to stimulators and activators of soluble guanylate cyclase in combination with an inhibitor of neutral endopeptidase and/or angiotensin AII antagonists and the use thereof for the treatment and/or prophylaxis of cardiovascular disorders, for example heart failure with preserved ejection fraction or heart failure with reduced ejection fraction, renal disorders, for example chronic kidney failure, urological disorders, lung disorders, disorders of the central nervous system, for regulation of cerebral perfusion, for example in the event of vascular cerebral states of dementia, for the treatment and/or prophylaxis of fibrotic disorders and other disease symptoms (e.g. end organ damage affecting the brain, kidney or heart).
    Type: Grant
    Filed: July 15, 2016
    Date of Patent: November 9, 2021
    Assignee: Bayer Pharma Aktiengesellschaft
    Inventors: Tobias Marquardt, Markus Follmann, Johannes-Peter Stasch
  • Patent number: 11160840
    Abstract: The present invention relates to a composition for preventing or treating a muscle disorder, which includes a chrysanthemum extract or 3,5-dicaffeoylquinic acid as an active ingredient, and specifically, it may be used to reduce mRNA expression of atrogin-1 and MuRF1, which are main biomarkers involved in muscle protein degradation and increase mRNA expression of the mTOR protein, which is a main biomarker involved in muscle protein formation, and myogenin and MyoD, which are biomarkers related to muscle differentiation, thereby reducing muscle loss, and thus the chrysanthemum extract or 3,5-dicaffeoylquinic acid can be used in prevention and treatment of a muscle disorder, or improvement in muscle function. In addition, the chrysanthemum extract or 3,5-dicaffeoylquinic acid increases the activity of SIRT1 and PGC-1?, which are the main biomarkers involved in exercise performance, thereby excellently enhancing exercise performance.
    Type: Grant
    Filed: November 30, 2017
    Date of Patent: November 2, 2021
    Assignees: Industry-Academic Cooperation Foundation, Yonsei University, Cosmax NBT, Inc., Cosmax NS, Inc.
    Inventors: Jae Kwan Hwang, Jun Gon Yun, Mi Bo Kim, Chang Hee Kim, Joon Hyung Lee, Do Wan Kwon, Su Young Choi, Jin Hak Kim, Ji Hwan Jang, Jeong Ho Geum, Min Son Kweon
  • Patent number: 11096918
    Abstract: An amorphous solid form of a compound comprising the angiotensin receptor antagonist (ARB) valsartan, the neutral endopeptidase inhibitor (NEPi) (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methylpentanoic acid ethyl ester and sodium cations is provided. This compound is useful for the treatment of hypertension and/or heart failure.
    Type: Grant
    Filed: September 23, 2019
    Date of Patent: August 24, 2021
    Assignee: NOVARTIS PHARMACEUTICALS CORPORATION
    Inventors: Lili Feng, Sven Erik Godtfredsen, Paul Allen Sutton, Mahavir Prashad, Michael J. Girgis, Bin Hu, Yugang Liu, Thomas J. Blacklock, Piotr Henryk Karpinski
  • Patent number: 10696620
    Abstract: Disclosed herein are compounds for use as antimicrobial agents, having a structure of formula (I):
    Type: Grant
    Filed: April 5, 2018
    Date of Patent: June 30, 2020
    Assignee: Boulos & Cooper Pharmaceuticals Pty Ltd
    Inventors: Allan James McKinley, Thomas V. Riley, Nigel Lengkeek, Scott Stewart, Ramiz Boulos
  • Patent number: 10689352
    Abstract: Solid state forms of trisodium vaisartan:sacubitril, processes for their preparation, pharmaceutical compositions containing such solid state forms and treatment methods using the pharmaceutical compositions are described.
    Type: Grant
    Filed: June 10, 2016
    Date of Patent: June 23, 2020
    Assignee: TEVA PHARMACEUTICALS INTERNATIONAL GMBH
    Inventors: Edislav Leksic, Dijana Skalec Samec, Damir Sahnic, Dejan Kisicek, Martina Hrkovac, Edi Topic
  • Patent number: 10668040
    Abstract: Nitrogen scavenging drugs such as glycerol phenylbutyrate can be administered safely to infants and toddlers with urea cycle disorders by adjusting the dosage based on one or more biomarkers selected from the group consisting of urinary-PAGN and plasma PAA:PAGN ratio.
    Type: Grant
    Filed: September 11, 2018
    Date of Patent: June 2, 2020
    Assignee: Horizon Therapeutics, LLC
    Inventors: Bruce Scharschmidt, Masoud Mokhtarani
  • Patent number: 10329236
    Abstract: Provided is a process for preparing 4-phenyl-1-butyric acid, comprising: reacting 4-phenyl-1-butanol with sodium chlorite, a nitroxyl radical catalyst and sodium hypochlorite in an organic solvent and a phosphate buffer; and quenching the reaction with sodium sulfite to produce 4-phenyl-1-butyric. Also provided is 4-phenyl-1-butyric acid prepared by such a process.
    Type: Grant
    Filed: September 6, 2017
    Date of Patent: June 25, 2019
    Assignee: Horizon Therapeutics, LLC
    Inventors: Huai-Chueh Chang, Steven S. Pfeiffer, Vasilios H. Iskos, Maki Uragami, Steven Weissman, Andrew Thompson
  • Patent number: 10233144
    Abstract: The present disclosure relates to a novel crystalline form of a compound of formula (I), preparation method and use thereof. The novel crystalline form in the present disclosure has good stability, low hygroscopicity, and remarkable purification effect in process. The novel crystalline form of the compound of formula (I) provided by the present disclosure can be used for the preparation of the drug for treating heart failure.
    Type: Grant
    Filed: March 18, 2016
    Date of Patent: March 19, 2019
    Assignee: Crystal Pharmatech Co., Ltd.
    Inventors: Minhua Chen, Yanfeng Zhang, Chaohui Yang, Shu Yu, Xiaoyu Zhang, Liang Zhang
  • Patent number: 10052301
    Abstract: The present invention provides a method for treating a cancer in a subject involving administering to the subject a compound of formula (II) or (II?): wherein R1, R2, R3, R4, R5, R6 and R7 are independently H, OH, alkoxy or alkylcarbonyloxy, or a pharmaceutically acceptable salt thereof. Also provided is a compound of formula (II) or (II)?, wherein R1 and R2 are independently OH, alkoxy or alkylcarbonyloxy, R3 and R4 are independently H, OH, alkoxy or alkylcarbonyloxy, R6 is H, alkoxy or alkylcarbonyloxy, R5 is H, OH or alkylcarbonyloxy, R6 is H or alkoxy, and R7 is H, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: May 17, 2015
    Date of Patent: August 21, 2018
    Assignee: ORX PHARMACEUTICAL CORPORATION
    Inventor: Alexander MacGregor
  • Patent number: 10004713
    Abstract: The present invention provides uses of chlorogenic acid in the preparation of medicaments for treatment of oligodendroglioma. Chlorogenic acid according to the present invention has an inhibitory action against oligodendroglioma, and can inhibit the growth of brain tumor stem cells, thus can partly substitute chemoradiation. Chlorogenic acid can alleviate the unwell response of patients caused by chemoradiation, and become a new medicinal therapeutic means and choose for treatment of oligodendroglioma.
    Type: Grant
    Filed: October 14, 2014
    Date of Patent: June 26, 2018
    Assignee: SICHUAN JIUZHANG BIOLOGICAL SCIENCE AND TECHNOLOGY CO., LTD.
    Inventors: Jie Zhang, Lina Zhu
  • Patent number: 9968582
    Abstract: This disclosure relates to pharmaceutical compositions useful for inhibiting the progression of urea cycle disorders and neurodegenerative disorders, such as Parkinson's disease, Alzheimer's disease, and multiple sclerosis. The pharmaceutical compositions may include glyceryl tribenzoate and glyceryl dibenzoate. The pharmaceutical compositions may be orally administered to the patient one time per day.
    Type: Grant
    Filed: January 16, 2015
    Date of Patent: May 15, 2018
    Assignee: Rush University Medical Center
    Inventor: Kalipada Pahan
  • Patent number: 9962356
    Abstract: The present invention is directed compositions derived from green coffee bean extract and methods for the use and manufacture of such compositions. The compositions of the invention have unique ratios of chlorogenic acids which offer a therapeutic effect in the treatment of a variety of conditions and disorders. Methods for using the compositions of the invention include, but not limited to, methods for treating obesity and methods for regulating serum lipids.
    Type: Grant
    Filed: June 18, 2017
    Date of Patent: May 8, 2018
    Assignee: Vidya Herbs, Inc.
    Inventors: Kodimule Shyam Prasad, Harakanahalli Lingaraju Basavegowda
  • Patent number: 9820485
    Abstract: The use of a polyhydroxylated polyaromatic compound, in particular of chicoric acid, for combating plant pests and phytosanitary composition comprising chicoric acid.
    Type: Grant
    Filed: February 12, 2015
    Date of Patent: November 21, 2017
    Assignee: INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE-INRA
    Inventors: Jean-Luc Poessel, Marie-Helene Sauge-Collet, Yvan Rahbe
  • Patent number: 9775822
    Abstract: The present invention is directed compositions derived from green coffee bean extract and methods for the use and manufacture of such compositions. The compositions of the invention have unique ratios of chlorogenic acids which offer a therapeutic effect in the treatment of a variety of conditions and disorders. Methods for using the compositions of the invention include, but not limited to, methods for treating obesity and methods for regulating serum lipids.
    Type: Grant
    Filed: July 30, 2015
    Date of Patent: October 3, 2017
    Assignee: Vidya Herbs, Inc.
    Inventors: Kodimule Shyam Prasad, Harakanahalli Lingaraju Basavegowda
  • Patent number: 9751825
    Abstract: The disclosure relates to TAK1 inhibitors, compositions, and uses related thereto. In certain embodiments, the disclosure relates to compounds of formula (I), pharmaceutical compositions having a compound of formula (I), and methods of treating or preventing cancer by administering an effective amount of a pharmaceutical composition having a compound of formula (I) to a subject in need thereof.
    Type: Grant
    Filed: July 19, 2012
    Date of Patent: September 5, 2017
    Assignee: Emory University
    Inventors: Huw M. L. Davies, Spandan Chennamadhavuni, Andrei Bakin
  • Patent number: 9718766
    Abstract: One aspect of the invention provides a composition of novel high penetration compositions (HPC) or a high penetration prodrug (HPP) for treatment of Parkinson's disease. The HPCs/HPPs are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, the HPPs are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPCs/HPPs can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate.
    Type: Grant
    Filed: September 15, 2015
    Date of Patent: August 1, 2017
    Assignee: Techfields Pharma Co., Ltd.
    Inventors: Chongxi Yu, Lina Xu
  • Patent number: 9616124
    Abstract: The present invention relates to the field of dietary supplements, and in particular to antiviral compositions and methods of use. Compositions are described involving various combinations of Andrographis, Astragalus, Eleuthero, Isatis, Lomatium, Pelargonium, Sambucus, Scute, and/or Zinc, optionally with additional components. These combinations of supplements synergistically reduce both severity and duration of viral infections, including in particular colds and influenza, as well as providing additional benefits.
    Type: Grant
    Filed: July 17, 2014
    Date of Patent: April 11, 2017
    Inventor: Jonathan S. Nimitz
  • Patent number: 9511120
    Abstract: The present invention is related to the use of the angiotensin-(1-9) peptide or peptides derived therefrom, which are biological or chemical analogs, for preparing medicaments useful for preventing, reverting, inhibiting and/or reducing hypertension and/or inducing vasodilation. Furthermore, this invention also comprises a vector overexpressing the homologous angiotensin-II converting enzyme (ACE2) for elevating the concentration in the blood and/or tissues of the angiotensin-(1-9) peptide. This vector may be adenovirus, retrovirus, lentivirus or adeno-associated virus containing the gene encoding for ACE2.
    Type: Grant
    Filed: April 5, 2012
    Date of Patent: December 6, 2016
    Assignees: PONTIFICA UNIVERSIDAD CATÓLICA DE CHILE, UNIVERSIDAD DE CHILE
    Inventors: Maria Paz Ocaranza Jeraldino, Jorge Emilio Jalil Milad, Sergio Alejandro Lavandero González, Mario Martin Chiong Lay, Luis Fernando Michea Acevedo
  • Patent number: 9289406
    Abstract: The present disclosure provides methods for treating hepatic encephalopathy (HE) and for optimizing and adjusting nitrogen scavenging drug dosage for subjects with HE.
    Type: Grant
    Filed: November 21, 2013
    Date of Patent: March 22, 2016
    Assignee: Horizon Therapeutics, Inc.
    Inventors: Bruce Scharschmidt, Masoud Mokhtarani
  • Patent number: 9227934
    Abstract: The invention relates to a new process for producing NEP inhibitors or prodrugs thereof, in particular NEP inhibitors comprising a ?-amino-?-biphenyl-?-methylalkanoic acid, or acid ester, backbone. In detail, the new processes, according to the present invention, are ultimately related to the synthesis of intermediates to prepare the above NEP inhibitors, namely compounds according to formula (1), or salt thereof, wherein R1 and R2 are, independently of each other, hydrogen or a nitrogen protecting group, and R3 is a carboxyl group or an ester group, preferably carboxyl group or alkyl ester.
    Type: Grant
    Filed: May 18, 2015
    Date of Patent: January 5, 2016
    Assignee: NOVARTIS AG
    Inventors: David Hook, Bernard Riss, Daniel Kaufmann, Matthias Napp, Erhard Bappert, Philippe Polleux, Jonathan Medlock, Antonio Zanotti-Gerosa
  • Patent number: 9073813
    Abstract: A process for the preparation of protoescigenin by hydrolysis of escin isolated from Aesculus hippocastanum. The process includes the following steps: a two-step hydrolysis first under acidic and then basic conditions, enrichment of the crude mixture of sapogenins with protoescigenin, an isolation of the mixture of sapogenins in a solid form, and a purification of the obtained solid and isolation of high purity protoescigenin. The invention also relates to protoescigenin monohydrate in a crystalline form and the preparation thereof. Protoescigenin is a polyhydroxy aglycone, which can be used as a synthon in the chemical modifications of naturally occurring saponins.
    Type: Grant
    Filed: January 3, 2013
    Date of Patent: July 7, 2015
    Assignees: INSTYTUT FARMACEUTYCZNY, WARSZAWSKI UNIWERSYTET MEDYCZNY
    Inventors: Mariusz Gruza, Oliwia Zegrocka-Stendel, Tomasz Giller, Grzegorz Grynkiewicz, Marta Laszcz, Kamil Jatczak
  • Patent number: 9061973
    Abstract: The invention relates to a new process for producing NEP inhibitors or prodrugs thereof, in particular NEP inhibitors comprising a ?-amino-?-biphenyl-?-methylalkanoic acid, or acid ester, backbone. In detail, the new processes, according to the present invention, are ultimately related to the synthesis of intermediates to prepare the above NEP inhibitors, namely compounds according to formula (1), or salt thereof, wherein R1 and R2 are, independently of each other, hydrogen or a nitrogen protecting group, and R3 is a carboxyl group or an ester group, preferably carboxyl group or alkyl ester.
    Type: Grant
    Filed: November 11, 2013
    Date of Patent: June 23, 2015
    Assignee: Novartis Pharmaceuticals Corporation
    Inventors: David Hook, Bernard Riss, Daniel Kaufmann, Matthias Napp, Erhard Bappert, Philippe Polleux, Jonathan Medlock, Antonio Zanotti-Gerosa
  • Patent number: 9040579
    Abstract: A pharmaceutical composition containing a mitochondrial electron transport chain enhancer (or an antioxidant) and a compound of formula (I) shown in the specification. This pharmaceutical composition can be used to treat neurodegenerative disorders.
    Type: Grant
    Filed: October 18, 2011
    Date of Patent: May 26, 2015
    Assignee: Chemigen
    Inventor: Yansheng Du
  • Publication number: 20150141476
    Abstract: The present invention relates to the use of a 2,5-dihydroxybenzene derivative of formula (I) or a pharmaceutically acceptable salt, solvate, isomer, or prodrug thereof for the treatment and/or prophylaxis of, inter alia, rosacea.
    Type: Application
    Filed: January 23, 2015
    Publication date: May 21, 2015
    Inventors: Pedro Cuevas Sànchez, Guillermo Gimenez Gallego, Inigo Saenz de Tejada Gorman, Javier Angulo Frutos, Serafin Valverde Lopez, Antonio Romero Garrido, Rosa Maria Lozano Puerto
  • Publication number: 20150132385
    Abstract: The present invention relates to nanocrystalline solid dispersion compositions having discrete particles, wherein each discrete particle comprises crystals of at least one pharmaceutical active; veterinary active; nutraceutical active dispersed in the matrix of at least one crystallization inducer and/or coexisting with crystals of crystallization inducer, optionally along with pharmaceutically acceptable excipients. The present invention also encompasses a novel one-step process for generation of nanocrystalline solid dispersions. The present invention is particularly of use for improving the dissolution of pharmaceutical actives, veterinary actives; nutraceutical actives exhibiting dissolution-limited bioavailability. Dissolution enhancement is because of the decreased crystallite size of the pharmaceutical active.
    Type: Application
    Filed: March 7, 2013
    Publication date: May 14, 2015
    Inventors: Arvind Kumar Bansal, Ajay Kumar Raju Dantuluri, Shete Ganesh Bhaskarao, Pawar Yogesh Bapurao
  • Publication number: 20150133495
    Abstract: Disclosed herein is a compound of Formula I or a pharmaceutically acceptable salt thereof, in which A, G, R1 and R2 are as defined herein. The compounds and pharmaceutical compositions of the compounds are suitable for the treatment of HCV infection in mammals and are also useful to modulate or inhibit NS3/4 dimerization.
    Type: Application
    Filed: November 13, 2014
    Publication date: May 14, 2015
    Inventor: Daniel Lamarre
  • Patent number: 9023892
    Abstract: A compound for use as an antimicrobial having a formula (A).
    Type: Grant
    Filed: December 21, 2010
    Date of Patent: May 5, 2015
    Inventors: Allan James McKinley, Thomas V. Riley, Nigel Lengkeek, Scott Stewart, Ramiz Boulos
  • Publication number: 20150119458
    Abstract: The present invention discloses a 4-((substituted phenyl)difluoromethyl)phenoxycarboxylic acid derivative and preparation process and use thereof. More specifically, the present invention relates to a compound of the following formula I, which is defined in the specification. The compounds according to the present invention can be used as PPAR agonists, and demonstrates a strong effect on reducing the levels of total cholesterol (TC), triglyceride (TG), and low density lipoprotein cholesterol (LDL-C) in blood plasma, and thus the compound according to the present invention can be used in the preparation of a medicament for treating or preventing hyperlipoidemia or cardio-cerebrovascular diseases caused by hyperlipoidemia, such as diabetes, atherosclerosis, stroke, coronary heart disease, etc. The present invention also relates to a novel intermediate compound for the preparation of the compound of formula I and preparation method thereof.
    Type: Application
    Filed: April 25, 2013
    Publication date: April 30, 2015
    Applicant: Zhejiang Hisun Pharmaceutical Co., Ltd.
    Inventors: Hua Bai, Jian Hong, Lifeng Cai, Hegeng Wei, Xiaoyu Liu, Xiaohe Zheng
  • Patent number: 9018255
    Abstract: The subject of the present invention are novel esters of (acyloxymethyl)acrylamide, a pharmaceutical composition containing them and their use in the production of drugs for the prophylaxis or treatment of oncogenic diseases and diseases connected with increased cell proliferation.
    Type: Grant
    Filed: October 16, 2011
    Date of Patent: April 28, 2015
    Assignees: Instytut Chemii Organicznej Polskiej Akademii Nauk, Warszawski Uniwersytet Medyczny
    Inventors: Ryszard Ostaszewski, Szymon Klossowski, Izabela Ziuzia, Angelika Szokalska, Marta Swiech, Jakub Golab
  • Publication number: 20150087703
    Abstract: The present invention provides a method and composition for treating a neurodegenerative disease. In particular, the present invention provides a method and composition to increase DJ-1 gene expression or DJ-1 protein activity to treat a neurodegenerative disease.
    Type: Application
    Filed: March 28, 2013
    Publication date: March 26, 2015
    Applicant: The Regents of the University of Colorado, a body corporate
    Inventors: Curt R. Freed, Wenbo Zhou
  • Publication number: 20150065570
    Abstract: An agent induces heat shock protein in human and animal cells. The agent includes at least one phenol compound that is a cinnamic acid derivative and at least one nonionic surfactant. The agent is useful in cosmetic preparations, food supplements and foodstuffs.
    Type: Application
    Filed: January 22, 2013
    Publication date: March 5, 2015
    Inventors: Sergey Yurievich LESHKOV, Nina Sergeevna VIKHRIEVA
  • Publication number: 20150056314
    Abstract: An improved method for producing a coffee bean extract containing beneficial compounds.
    Type: Application
    Filed: October 31, 2014
    Publication date: February 26, 2015
    Inventor: Christine C. Fields
  • Publication number: 20150051256
    Abstract: The present invention provides a medicament that suppresses (or mitigates) various neurological symptoms caused by a peripheral nerve disorder induced by an anti-cancer agent.
    Type: Application
    Filed: October 28, 2014
    Publication date: February 19, 2015
    Applicant: Takeda Pharmaceutical Company Limited
    Inventor: Naomi Kitamoto
  • Patent number: 8956589
    Abstract: Disclosed are a curcumin derivative or a salt thereof, which contains a fluorine atom, represented by formula (I): (wherein R1a and R1b are each independently a hydrogen atom, alkyl, acetyl, or methoxycarbonyl; R2s are each independently a fluorine atom, CHF2—, CF3—, CHF2O—, or CF3O—; R3s are each independently a hydrogen atom or a fluorine atom; A is alkyl, cyano, carboxyl, alkoxycarbonyl, or R4—(CH2)m—; R4 is hydroxy, carboxy, cyano, acetyloxy, alkoxycarbonyl, alkoxyalkoxy, hydroxyalkoxy, or CONR5R6; R5 and R6 are each independently a hydrogen atom or alkyl; and m is an integer from 1 to 5), and a diagnostic imaging agent for diagnosing a disease in which an amyloid ? peptide aggregate accumulates, the diagnostic imaging agent containing a compound having a 1,3-dicarbonyl structure, wherein the compound exists in a keto form and an enol form, and the keto form and the enol form have different affinities, respectively, to the amyloid ? peptide aggregate.
    Type: Grant
    Filed: February 26, 2010
    Date of Patent: February 17, 2015
    Assignee: Shiga University of Medical Science
    Inventors: Ikuo Tooyama, Hiroyasu Taguchi, Shigehiro Morikawa, Makoto Urushitani, Daijiro Yanagisawa, Tomone Nagae, Nobuaki Shirai, Koichi Hirao, Masanari Kato, Hirohiko Kimura, Takashi Okada
  • Publication number: 20150038581
    Abstract: In recognition of the need to develop novel therapeutic agents, the present invention provides novel histone deacetylase inhibitors. These compounds include an ester bond making them sensitive to deactivation by esterases. Therefore, these compounds are particularly useful in the treatment of skin disorders. When the compounds reaches the bloodstream, an esterase or an enzyme with esterase activity cleaves the compound into biologically inactive fragments or fragments with greatly reduced activity Ideally these degradation products exhibit a short serum and/or systemic half-life and are eliminated rapidly. These compounds and pharmaceutical compositions thereof are particularly useful in treating cutaneous T-cell lymphoma, neurofibromatosis, psoriasis, hair loss, skin pigmentation, and dermatitis, for example. The present invention also provides methods for preparing compounds of the invention and intermediates thereto.
    Type: Application
    Filed: March 6, 2014
    Publication date: February 5, 2015
    Inventors: James Elliot Bradner, Ralph Mazitschek
  • Publication number: 20150011629
    Abstract: Methods for modulating the level of a chemokine in a cell by administering to a cell an effective amount of a depside or an anthocyanin are provided. More particularly, a method for modulating the level of a chemokine in a cell by administering to a cell an effective amount of a depside having the structure of formula (IV): Formula (IV) wherein R is selected from H or CH3 or an anthocyanin selected from cyanidin 3-glucoside, delphinidin 3-glucoside, or combinations thereof, or an enantiomer, optical isomer, diastereomer, N-oxide, crystalline form, hydrate, or pharmaceutically acceptable salt thereof is provided. Also provided are compounds according to Formulas I-IV, pharmaceutical compositions, unit dosage forms, and food or feed supplements containing such compounds.
    Type: Application
    Filed: September 22, 2014
    Publication date: January 8, 2015
    Applicant: The Trustees of Columbia University in the City of New York
    Inventors: Jeanine D'Armiento, Kurt Reynertson, Edward Kennelly, Alison Wallace
  • Publication number: 20150004232
    Abstract: Dermal delivery compositions are provided. Aspects of the dermal delivery compositions include the presence of active agent-calcium phosphate particle complexes, where these complexes include uniform, rigid, spherical nanoporous calcium phosphate particles associated with one or more active agents. Also provided are methods of using the compositions in active agent delivery applications.
    Type: Application
    Filed: April 22, 2014
    Publication date: January 1, 2015
    Applicant: Laboratory Skin Care, Inc.
    Inventor: Zahra Mansouri
  • Patent number: 8921420
    Abstract: Method for preparing 3,5-dicaffeoylquinic acid and certain derivatives thereof, and use thereof in the preparation of plant-protection products. Method for combating aphids using 3,5-dicaffeoylquinic acid and certain derivatives thereof.
    Type: Grant
    Filed: January 30, 2009
    Date of Patent: December 30, 2014
    Assignee: Institut National de la Recherche Agronomique
    Inventors: Jean-Luc Poessel, Marie-Hélène Collet, Yves Noel Elie Rahbe
  • Publication number: 20140378541
    Abstract: Synthetic polyphenolic compounds of formula (I), their modes of synthesis, and pharmaceutical compositions thereof are provided herein. Use of the compounds and compositions described herein for treating cancer and for treating metabolic disorders is also provided.
    Type: Application
    Filed: June 15, 2012
    Publication date: December 25, 2014
    Applicants: WAYNE STATE UNIVERSITY, THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY, HONG KONG POLYTECHNIC UNIVERSITY
    Inventors: Tak-Hang Chan, Sreedhar Pamu, Qing Ping Dou, Di Chen
  • Publication number: 20140378459
    Abstract: [Problem] Provided is a compound which is useful as an agent for preventing and/or treating renal diseases. [Means for Solution] The present inventors have conducted extensive studies on compounds having a trypsin inhibitory action, and as a result, they have found that a guanidinobenzoic acid compound has a trypsin inhibitory action, thereby completing the present invention. The guanidinobenzoic acid compound of the present invention can be used as an agent for preventing and/or treating renal disease as an agent which will substitute low-protein diet therapy, and an agent for preventing and/or treating trypsin-related diseases, for example, pancreatitis, gastroesophageal reflux disease, hepatic encephalopathy, influenza, and the like.
    Type: Application
    Filed: September 14, 2012
    Publication date: December 25, 2014
    Applicant: ASTELLAS PHARMA INC.
    Inventors: Jiro Fujiyasu, Kazuhiko Ohne, Susumu Yamaki, Tomoyoshi Imaizumi, Takeshi Hondo, Keisuke Matsuura, Tomohki Satou, Satoshi Sasamura
  • Publication number: 20140371310
    Abstract: Disclosed herein are compounds and compositions useful for reducing the risk of infection. In particular, disclosed herein are mandelic acid condensation polymers, compositions comprising such compounds, processes for producing such compounds, and methods of using such compounds.
    Type: Application
    Filed: November 30, 2012
    Publication date: December 18, 2014
    Inventors: Robert A. Anderson, JR., Xiao-Hui Diao, Lourens J.D. Zaneveld, Calvin J. Chany, II, Aleksej Krunic, Donald P. Waller, Duane L. Venton, Sanjay Jain
  • Patent number: 8907117
    Abstract: Synthetic dicinnamate compounds and their analogs are disclosed that exhibit anti-tumor activity and/or an anti-inflammatory activity, and have beneficial activity principally in destroying cancer cells. Furthermore, methods for the extraction of the extracts are disclosed.
    Type: Grant
    Filed: September 10, 2012
    Date of Patent: December 9, 2014
    Inventors: Henry Lowe, Joseph L. Bryant
  • Publication number: 20140343138
    Abstract: In one aspect, the invention relates to compounds having the formula: where R1-R6, a, b, and Z are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.
    Type: Application
    Filed: February 14, 2014
    Publication date: November 20, 2014
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Adam D. Hughes, Erik Fenster, Melissa Fleury, Roland Gendron, Edmund J. Moran
  • Patent number: 8889237
    Abstract: Provided are an excipient system and a medical container for an erythrocyte enriched liquid. The excipient system is prepared by adding a hemolysis inhibitor and a surfactant to an erythrocyte storage solution. Herein, the surfactant has an HLB value of 13 or more, and the number of oxyethylene groups at a hydrophilic segment in the molecular structure of the surfactant is 20 or more. The inside of the medical container is filled with the excipient system for an erythrocyte enriched liquid.
    Type: Grant
    Filed: February 16, 2011
    Date of Patent: November 18, 2014
    Assignee: Terumo Kabushiki Kaisha
    Inventor: Norihiko Takeda
  • Publication number: 20140336185
    Abstract: Compounds that bind the glucagon-like peptide 1 (GLP-1) receptor, methods of their synthesis, methods of their therapeutic and/or prophylactic use, and methods of their use in stabilizing GLP-1 receptor in vitro for crystallization of the GLP-1 receptor are provided. Certain compounds may have activity as modulators or potentiators with respect to glucagon receptor, GIP receptor, GLP-1 and GLP-2 receptors, and PTH receptor on their own or in the presence of receptor ligands such as GIP (1-42), PTH (1-34), Glucagon (1-29), GLP-2 (1-33), GLP-1 (7-36), GLP-1 (9-36), oxyntomodulin and exendin variants.
    Type: Application
    Filed: May 31, 2012
    Publication date: November 13, 2014
    Inventors: Marcus F. Boehm, Esther Martinborough, Manisha Moorjani, Junko Tamiya, Liming Huang, Thomas Fowler, Andrew Novak, Premji Meghani, Enugurthi Brahmachary, Adam Richard Yeager
  • Publication number: 20140336194
    Abstract: The present invention provides the use of a neutral endopeptidase inhibitor, in the manufacture of a medicament for the treatment, amelioration and/or prevention of contrast-induced nephropathy. The invention also relates to the use of a compound of Formula I: wherein R1, R2, R3, R5, X, A3, B1, s and n are defined herein, for the treatment, amelioration and/or prevention of contrast-induced nephropathy. The present invention further provides a combination of pharmacologically active agents for use in the treatment, amelioration and/or prevention of contrast-induced nephropathy.
    Type: Application
    Filed: July 28, 2014
    Publication date: November 13, 2014
    Applicant: NOVARTIS AG
    Inventor: Shi Yin FOO
  • Publication number: 20140329900
    Abstract: The present invention concerns compounds, compositions containing these compounds, and methods of using these compounds and compositions as inhibitors of Stat3 signaling, Stat3 dimerization, Stat3-DNA binding, Stat5-DNA binding, and/or aberrant cell growth in vitro or in vivo, e.g., as anti-cancer agents for treatment of cancer, such as breast cancer. The compounds of the invention include, but are not limited to, NSC 74859 (S31-201), NSC 42067, NSC 59263, NSC 75912, NSC 11421, NSC 91529, NSC 263435, and pharmaceutically acceptable salts and analogs of the foregoing. Other non-malignant diseases characterized by proliferation of cells that may be treated using the compounds of the invention, but are not limited to, cirrhosis of the liver; graft rejection; restenosis; and disorders characterized by a proliferation of T cells such as autoimmune diseases, e.g., type 1 diabetes, lupus and multiple sclerosis.
    Type: Application
    Filed: April 7, 2014
    Publication date: November 6, 2014
    Applicants: H. Lee Moffitt Cancer Center And Research Institute, Inc., University of Central Florida, University of South Florida
    Inventors: JAMES TURKSON, SAID M. SEBTI, WAYNE GUIDA, MAN LUN YIP, NICHOLAS LAWRENCE, HARSHANI RITHMA LAWRENCE, BENJAMIN GREEDY
  • Patent number: 8877808
    Abstract: This invention describes a method of preventing and treating inflammatory skin diseases by topical application of aurin tricarboxylic acid and its derivatives. Such diseases are characterized by immune attack, especially involving aberrant complement activation. The diseases include, but are not limited to, androgenetic alopecia (baldness), seborrheic dermatitis/dandruff, allergic dermatitis, primary cicatricial alopecia, pemphigus, psoriasis, discoid lupus erythematosis, and dermatitus herpetiformis.
    Type: Grant
    Filed: December 6, 2012
    Date of Patent: November 4, 2014
    Assignee: Aurin Biotech Inc.
    Inventors: Patrick L. McGeer, Moonhee Lee, Douglas N. Bell
  • Publication number: 20140308265
    Abstract: The claimed invention is directed to compositions and methods effective in preventing microbial contamination or reducing microbial count associated with a contaminated surface, comprising a biocidal system comprised of a primary biocide, a pH buffer agent, a surfactant, all in an aqueous based carrier, wherein the compositions may be considered environmentally friendly.
    Type: Application
    Filed: November 6, 2012
    Publication date: October 16, 2014
    Inventors: Burt R. Sookram, John W. Veenstra